Aclaris Therapeutics ACRS
NASDAQ ACRS
$4.41 -0.85 (-16.16%)
At close: Oct 1, 2026 · 4:00 PM EDT

Aclaris Therapeutics (ACRS) Liabilities and Shareholders Equity (2014 - 2026)

Updated

Aclaris Therapeutics' Liabilities and Shareholders Equity was $179.69 million in Q2 2026, down 5.0% from $189.15 million a year earlier and down 9.6% from the prior quarter.

Analysis

Aclaris Therapeutics (ACRS) Liabilities and Shareholders Equity (2014 - 2026) Analysis & Trends

At the end of FY2025, Liabilities and Shareholders Equity at Aclaris Therapeutics came in at $160.46 million, down 27.2% from FY2024.

  • Liabilities and Shareholders Equity shows a five-year compound annual growth rate of 17.8% (FY2020 to FY2025).
  • In earlier years, Liabilities and Shareholders Equity was $220.33 million in FY2024 (+11.6%), $197.41 million in FY2023 (-22.5%), $254.6 million in FY2022 (+1.3%) and $251.21 million in FY2021 (+254.9%).
  • Quarterly Liabilities and Shareholders Equity has moved between $160.46 million (Q4 2025) and $277.98 million (Q2 2022) over five years.
  • Compared with a year earlier, Liabilities and Shareholders Equity was higher in four of the last eight quarters, with an average decline of 1.2%.
  • The best year-over-year quarter for Liabilities and Shareholders Equity over five years was Q3 2021 (growth of 266.5%); the worst was Q2 2024 (a decline of 31.6%).
  • Per Business Quant data, ACRS's Liabilities and Shareholders Equity in the three quarters before Q2 2026 was $198.72 million (Q1 2026), $160.46 million (Q4 2025) and $175.53 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 201.06 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 135.12 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn 129.80 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 122.03 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 115.83 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 95.64 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn 49.36 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 201.13 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 27.42 Bn
10 Aclaris Therapeutics 735.48 Mn 735.48 Mn 1.41 Mn 179.69 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 179.69 Mn
Mar 31, 2026 198.72 Mn
Dec 31, 2025 160.46 Mn
Sep 30, 2025 175.53 Mn
Jun 30, 2025 189.15 Mn
Mar 31, 2025 198.09 Mn
Dec 31, 2024 220.33 Mn
Sep 30, 2024 182.39 Mn
Jun 30, 2024 161.07 Mn
Mar 31, 2024 174.07 Mn
Dec 31, 2023 197.41 Mn
Sep 30, 2023 218.35 Mn
Jun 30, 2023 235.65 Mn
Mar 31, 2023 229.71 Mn
Dec 31, 2022 254.60 Mn
Sep 30, 2022 267.63 Mn
Jun 30, 2022 277.98 Mn
Mar 31, 2022 226.53 Mn
Dec 31, 2021 251.21 Mn
Sep 30, 2021 263.49 Mn
API Access

Aclaris Therapeutics Liabilities and Shareholders Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=ACRS&period=max&api_key=YOUR_API_KEY